References
1. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S.
Prevalence and type distribution of human papillomavirus in carcinoma
and intraepithelial neoplasia of the vulva, vagina and anus: a
meta-analysis. Int J Cancer. 2009;124(7):1626-36.
2. Hillemanns P, Wang X. Integration of HPV-16 and HPV-18 DNA in vulvar
intraepithelial neoplasia. Gynecol Oncol. 2006;100(2):276-82.
3. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in
the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol.
2006;107(5):1018-22.
4. Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ
and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007-a
nationwide population-based study. Gynecol Oncol. 2011;122(1):45-9.
5. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural
history of vulvar intraepithelial neoplasia III based on enough
evidence? A systematic review of 3322 published patients. Gynecol Oncol.
2005;97(2):645-51.
6. Lawrie TA, Nordin A, Chakrabarti M, Bryant A, Kaushik S, Pepas L.
Medical and surgical interventions for the treatment of usual-type
vulval intraepithelial neoplasia. Cochrane Database Syst Rev.
2016(1):CD011837.
7. Tzellos TG, Sardeli C, Lallas A, Papazisis G, Chourdakis M, Kouvelas
D. Efficacy, safety and tolerability of green tea catechins in the
treatment of external anogenital warts: a systematic review and
meta-analysis. J Eur Acad Dermatol Venereol. 2011;25(3):345-53.
8. Melzack R. The McGill Pain Questionnaire: major properties and
scoring methods. Pain. 1975;1(3):277-99.
9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple
practical measure for routine clinical use. Clin Exp Dermatol.
1994;19(3):210-6.
10. Fehr MK, Baumann M, Mueller M, Fink D, Heinzl S, Imesch P, et al.
Disease progression and recurrence in women treated for vulvovaginal
intraepithelial neoplasia. J Gynecol Oncol. 2013;24(3):236-41.
11. Wang YQ, Lu JL, Liang YR, Li QS. Suppressive Effects of EGCG on
Cervical Cancer. Molecules. 2018;23(9).
12. Qiao Y, Cao J, Xie L, Shi X. Cell growth inhibition and gene
expression regulation by (-)-epigallocatechin-3-gallate in human
cervical cancer cells. Arch Pharm Res. 2009;32(9):1309-15.
13. Kumar S, Jena L, Galande S, Daf S, Mohod K, Varma AK. Elucidating
Molecular Interactions of Natural Inhibitors with HPV-16 E6 Oncoprotein
through Docking Analysis. Genomics Inform. 2014;12(2):64-70.
14. Tatti S, Stockfleth E, Beutner KR, Tawfik H, Elsasser U, Weyrauch P,
et al. Polyphenon E: a new treatment for external anogenital warts. Br J
Dermatol. 2010;162(1):176-84.
15. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC,
Eijkemans MJ, et al. Treatment of vulvar intraepithelial neoplasia with
topical imiquimod. N Engl J Med. 2008;358(14):1465-73.
16. Tristram A, Hurt CN, Madden T, Powell N, Man S, Hibbitts S, et al.
Activity, safety, and feasibility of cidofovir and imiquimod for
treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre,
open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15(12):1361-8
17. Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl
TG, et al. The 2015 International Society for the Study of Vulvovaginal
Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions.
Obstet Gynecol. 2016;127(2):264-8.1.